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ABSTRACT
This review assesses the protective effect of ACEIs and 
ARBs on microalbuminuria in diabetic patients and 
identifying the preferred type based on their beneficial 
effects in addition to their blood pressure-reducing 
effect in diabetic patients with microalbuminuria and 
adverse drug reaction profile. In this review, articles 
published between 2001 and 2019 are included and 
MEDLINE search was used with key words such as 
diabetes, microalbuminuria, angiotensin II receptor 
antagonists, and ACEIs. ARBs reduced the risks of end 
stage renal disease (ESRD) and two-fold rise in the se-
rum creatinine level; ACEIs did not reduce the risks of 
ESRD in an analysis of studies including both type 1 and 
type 2 diabetic patients. However, a meta-analytical 
review or study needs to be conducted to evaluate the 
comparative effects of ARBs and ACEIs in either type 1 
or type 2 diabetic patients. Early treatment with ACEIs 
or ARBs decreased the risk of microalbuminuria in pa-
tients with type 2 diabetes. Telmisartan is found to be 
beneficial in microalbuminuria or diabetic nephropa-
thy. Long-term therapy with higher dose of irbesartan 
resulted in consistent protective effects on the renal 
functions even after its withdrawal. ACEIs or ARBs are 
consideredas the 1st line therapy in both type 1 and 2 
diabetic patients with microalbuminuria. ARBs are defi-
nitely preferred for patients who cannot tolerate ACE 
inhibitors. ARBs may be preferred over ACEIs due to 
their predominant renal protective effects in addition 
to their beneficial effect of improving blood pressure 
in type 2 diabetes mellitus. However, the comparative 
effects of ARBs and ACEIs in either type 1 or type 2 
diabetic patients with microalbuminuria needs to be 
further evaluated in a randomized controlled study. 
(Clin Diabetol 2020; 9)
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Introduction
Albuminuria is developed in 1/3rd of the diabetic 
patients. There is higher risk of all-cause mortality and 
end-stage renal disease (ESRD) in diabetic patients with 
albuminuria. Cardiovascular disease and mortality can 
be predicted on the basis of microalbuminuria as it is an 
indicator of endothelial dysfunction. Microalbuminuria 
is also reported in cases with hypertension, dyslipidae-
mia, renal malfunction, obesity, and smoking; all these 
are contributors to the development of atherosclerosis. 
Hyperactivity of renin–angiotensin system leads to 
the development of cardiovascular events in diabetic 
patients with microalbuminuria [1–3].
It has been reported in studies that angiotensin-
-converting enzyme inhibitors (ACEIs) or angiotensin II 
receptor antagonists (ARBs) lead to a reduction in the 
cardiovascular mortality rate and an improvement 
in glomerular filtration rate in hypertensive diabetic 
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patients with microalbuminuria, macroalbuminuria, or 
normoalbuminuria [1, 4, 5].
This review is carried out to assess the protective ef-
fect of ACEIs and ARBs on microalbuminuria in diabetic 
patients and to identify the preferred ACEIs and ARBs 
based on their beneficial effects in addition to their 
blood pressure-reducing effect in diabetic patients with 
microalbuminuria and adverse drug reaction profile. 
The safety aspects of ACEIs and ARBs are also discussed.
Methodology
This review includes articles published between 
2001 and 2019. A MEDLINE search was used for it. The 
following words were used while searching articles: 
diabetes, microalbuminuria, angiotensin II Receptor 
antagonists, angiotensin-converting enzyme inhibi-
tors. Articles on clinical trials, meta-analysis reports, 
guidelines and past reviews are included. Thus, hu-
man clinical studies in relation to the effect of ACEIs 
and ARBs including ramipril, perindopril, olmesartan, 
losartan, irbesartan, telmisartan etc. especially on 
microalbuminuria in diabetic patients are considered. 
Non-renal parameter-related clinical studies and pre-
clinical studies were excluded for this review. Possible 
mechanisms in the protective effect of ACEIs and ARBs 
in diabetic patients with microalbuminuria are also 
discussed in this review.
Microalbuminuria in diabetes
A review article by Satchell et al. [6] indicates the 
following: microalbuminuria is a predominant risk fac-
tor for CV (cardiovascular) disease and advancement 
in renal impairment, especially in diabetic population, 
though it seems to be valid in non-diabetic individuals 
as well; it is well-known that the diabetic population 
has the tendency to develop renal complications. It is 
essential to know the pathological and physiological 
mechanisms behind the development of microalbu-
minuria to strategize therapies needed to prevent and 
treat microalbuminuria [6].
Damage to the endothelial glycocalyx is an essential 
feature. Various mediators are involved in the damage 
process, such as reactive oxygen species (ROS), vascular 
endothelial growth factor (VEGF) and proinflammatory 
cytokines. Impairment in the pathway of the endothe-
lium cell and podocyte leads to endothelial damage and 
aggravates the impairment. Impairment in glomerular 
podocyte and its loss is involved during a damaging 
process of advancement of microalbuminuria to overt 
nephropathy (macroalbuminuria) [6].
It is reported that damage to the endothelial 
glycocalyx is predominantly involved in microalbumi-
nuria and generalised endothelial dysfunction, and in 
microvascular and macrovascular complications. There-
fore, treatments targeting the endothelial glycocalyx 
could be beneficial in microalbuminuria in the diabetic 
population. A decrease in microalbuminuria could help 
improve endothelial dysfunction and may be beneficial 
in reducing the risk of cardiovascular diseases [6].
The American Diabetes Association suggests the 
evaluation of albuminuria in type 2 diabetes population 
initially at the time of diagnosis of diabetes and every 
year afterwards [7].
Another review by Basiet al. [8] indicates that ACE 
inhibitor or ARB therapy is recommended for patients 
with microalbuminuria or obvious proteinuria. Maximi-
zation of the dosages of ACE inhibitor or ARB therapy 
is useful during the management of albuminuria with 
regular monitoring. ACE inhibitor or ARB therapy is 
useful to reduce hypertension. But, if the blood pres-
sure is not controlled, add-on therapy with other anti-
hypertensives could be beneficial to maintain the blood 
pressure. Other therapies, such as statins, renin inhibi-
tors, and glycosaminoglycans, have also been found to 
be effective in reducing urinary albumin excretion [8].
Clinical efficacy of ACEIs and ARBs on 
microalbuminuria in diabetic patients
As per a systematic review and meta-analysis by 
Wang et al. [1] ACEIs and ARBs result in similar improve-
ment in microalbuminuria in patients with diabetes and 
albuminuria. It was noted that ARBs led to a significant 
reduction of the risk of end-stage renal disease (ESRD) 
in patients with diabetes and albuminuria. Most impor-
tantly, ACEIs did not show this reno-protective effect 
of reducing the risk of ESRD. This was a meta-analysis 
of twenty-six randomized controlled clinical studies 
including a big population of nearly ten thousand 
patients. ACEIs and ARBs also showed reduction in the 
risk of two-fold increase in the serum creatinine level. 
The improvement in microalbuminuria was similar with 
ACEIs and ARBs. It can be concluded from this meta-
analysis that ARBs might be the preferred therapy over 
ACEIs due to their beneficial effect on renal functions. 
However, the researchers incorporated both type 1 
and type 2 diabetic patients with albuminuria in this 
meta-analysis. Therefore, there could be the risk of bias. 
Thus, a meta-analytical study needs to be conducted 
to evaluate the comparative effects of ARBs and ACEIs 
especially in either type 1 or type 2 diabetic patients [1].
Persson et al. [4] evaluated the impact of ACEIs or 
ARBs on the prevention of microalbuminuria in patients 
with type 2 diabetes and normoalbuminuria. They con-
cluded that the risk of microalbuminuria for patients 
with type 2 diabetes and normoalbuminuria is signifi-
cantly lower with ACEIs or ARBs. The conclusion was 
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reached based on the meta-analysis of six randomized 
controlled clinical trials on nearly seventeen thousand 
patients with type 2 diabetes and normoalbuminuria. 
Unlike the meta-analysis report by Wang et al. [1], 
all-cause mortality was reduced to a certain extent 
with both ACEIs and ARBs by Persson et al. Studies on 
the following ACEIs or ARBs were considered for this 
review: enalapril, ramipril, trandolapril, candesartan, 
perindopril and olmesartan [4].
Uzuet al. [3] reported in their study that both ARBs 
and aliskiren, a direct renin inhibitor (DRI), reduced 
albuminuria significantly in hypertensive patients with 
type 2 diabetes. Moreover, albuminuria decreased 
significantly with ARBs in patients with high-normal 
albuminuria and DRI did not reduce albuminuria in 
similar patients. ARBs showed similar effectiveness to 
that of DRI in reducing urinary excretion of albumin, 
angiotensinogen, urinary albumin-to-creatinine ratio, 
and systolic and diastolic blood pressure. Thus, it in-
dicates that DRI is not superior to ARBs. Patients were 
treated with the following ARBs in this study: valsartan, 
telmisartan, olmesartan, candesartan, losartan, irbesar-
tan, azilsartan [3].
A choice of ACEIs and ARBs in diabetic  
patients with microalbuminuria
The following are the results from different studies 
for individual ACEIs and ARBs to conclude a choice of 
ACEIs and ARBs in diabetic patients with microalbu-
minuria.
Clinical efficacy of ramipril
As per the DIABHYCAR study (2004), no beneficial 
effect was found on ESRD or two-fold rise in serum cre-
atinine with the ACE inhibitor ramipril. The same study 
indicates no beneficial effect with low dose (1.25 mg) 
ramipril once daily on cardiovascular and renal out-
comes of patients with type 2 diabetes and albuminu-
ria, although a slight reduction in blood pressure and 
urinary albumin was observed [9].
Clinical efficacy of perindopril
In a placebo-controlled clinical trial conducted by 
Yao et al. on Asian patients, perindopril reduced urinary 
albumin excretion rate (AER) significantly in patients 
with initial stage of diabetic nephropathy with normal 
blood pressure and microalbuminuria during the one-
and-half-year treatment [10].
Jerums et al. [11] reported the following results in 
a placebo-controlled i.e. six-year follow-up study with 
perindopril, maintenance of albumin excretion rate 
(AER), reduction in GFR in Australian type 2 diabetic 
patients with normal blood pressure and microalbu-
minuria. The blood pressure remained normal in 83% 
of patients with perindopril. A significantly smaller 
number of patients developed macroalbuminuria [11].
Another double-blind study conducted by Kopf et 
al. concluded that urinary albumin excretion rate was 
maintained by perindopril in patients with insulin-
dependent diabetes mellitus and mild-to-moderate 
hypertension and stable microalbuminuria, and perin-
dopril therapy was found to be safe as well [12].
Clinical efficacy of olmesartan
In a study conducted by Raff et al. [13] it was 
found that olmesartan (OLM) prolonged the onset of 
the development of microalbuminuria in type 2 diabetic 
patients. Moreover, OLM prolonged the development 
of ECG signs of cardiac structural adaptation and left 
ventricular remodelling in type 2 diabetic patients [13].
Clinical efficacy of losartan
The RENAAL study seems to be a landmark work 
to show the following benefits with losartan therapy 
in patients with type 2 diabetes and nephropathy: 
reduction in the incidence of ESRD and two-fold rise 
in the serum creatinine level, 35% showed reduction 
in the level of proteinuria and good tolerance were 
documented with this drug. However, this study did not 
report the effect of the therapy on microalbuminuria. 
Moreover, there was no impact of losartan on the rate 
of death [14, 15].
A review of a clinical study by Ruilope et al. [16] 
indicates that losartan appears to be an essential 
therapy in type 2 diabetic patients with nephropathy in 
addition to dietary therapy for proteinuria and diabetes. 
In addition to blood pressure lowering effect, a renal 
protective benefit of losartan helps delay the initiation 
of dialysis or kidney transplantation [16].
According to a study conducted by Woo et al., 
losartan leads to an effective reduction in the urinary 
excretion of transforming growth factor (TGF)-beta and 
albumin in type 2 DM patients with microalbuminuria 
during a six-month therapy in addition to its property 
of effective reduction in arterial blood pressure [17].
A long-term randomized clinical study conducted 
by Weil et al. [18] indicated that losartan therapy 
reduced the mesangial fractional volume in type 2 
diabetic American-Indian patients with microalbuminu-
ria. Thus, losartan therapy helped preserve the kidney 
structure in these patients [18].
A randomized controlled-study by Agha et al. [19] 
concluded that losartan demonstrated a significant 
reduction in proteinuria in patients with normoten-
sive type 2 diabetes mellitus (T2DM) patients with 
early nephropathy. This study indicates that the effect 
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of losartan seems to be beyond its blood pressure 
reducing effect. This was a ten-month study on 361 
patients. Eighty percent of the patients reported sig-
nificant reduction in albuminuria by more than 30%. 
The anti-albuminuric effect of losartan was a reversible 
impact [19].
A similar beneficial effect of losartan on the urinary 
excretion of albumin was demonstrated in a multi-
centric randomized, double-blind, placebo-controlled 
clinical study conducted by Zandbergen et al. [20]. 
A 25–30% relative reduction was observed in this study 
with two different dosages through a ten-week therapy. 
This reemphasizes the effect of losartan on proteinuria 
possibly not associated with blood pressure reducing 
effect. Additionally, the safety of losartan was estab-
lished with normotensive patients [20].
Clinical efficacy of irbesartan
In a double-blind placebo-controlled randomized 
study, Andersen et al. [21] reported a persistent re-
duction of microalbuminuria after withdrawal of a 
two-year high-dose (300 mg, once daily) irbesartan 
treatment on hypertensive type 2 diabetic patients 
with persistent microalbuminuria. This indicates a 
long-term renal protective effect of high-dose irbesar-
tan treatment. This study also concluded that placebo 
and irbesartan 150-mg groups demonstrated increase 
in urinary albumin excretion. Most importantly, it was 
decreased persistently and significantly by 47% in the 
high-dose irbesartan group [21].
Clinical efficacy of telmisartan
Furat et al. [2] reported in a controlled study that 
telmisartan was beneficial for decreasing systemic 
inflammation and levels of urinary albumin excretion 
in patients who had type 2 diabetes mellitus and had 
undergone coronary artery bypass surgery. Microalbu-
minuria levels between the groups differed significantly 
in the pre-operative period, first hour postoperatively 
and fifth day post-operatively. C-reactive protein levels 
between the groups differed significantly on the fifth 
day post-operatively [2].
A review by Schmieder et al. [22] demonstrated 
that the effect of telmisartan on kidney function 
benefits in patients with microalbuminuria or overt 
diabetic nephropathy. They reported that telmisartan 
offers benefits at all the stages of the renal abnormali-
ties in patients with type 2 diabetes. Telmisartan delays 
the progression to overt nephropathy in patients with 
microalbuminuria. The effectiveness of telmisartan is 
similar to angiotensin-converting enzyme inhibitors, 
but with a greater tolerance than angiotensin-con-
verting enzyme inhibitors. The effect of telmisartan on 
protein excretion in diabetic nephropathy appears to be 
better than that of losartan and equivalent to that of 
valsartan. In the ONTARGET study, telmisartan offered 
a comparable cardiovascular protection to ramipril in 
diabetic patients [22].
Clinical efficacy of ACEIs plus ARBs
In a study conducted by Joshi et al. [23] it was 
found that the fixed dose combination of losartan and 
ramipril demonstrated a good to excellent efficacy in 
approximately 98% patients and accomplished a target 
blood pressure in nearly 79% patients with a 12 week-
-therapy. The combination offered a reduction in the 
urinary albumin excretion in most of the patients with 
microalbuminuria and proteinuria. This was an open, 
non-comparative, multicentric clinical study conducted 
on Indian patients. All the patients were treated with 
combination of losartan + ramipril in two fixed doses. 
Nearly 21% patients obtained normoalbuminuria with 
this therapy [23].
However, a study conducted by Tütüncü et al. 
concluded that ACE inhibitors and angiotensin II re-
ceptor blockers lead to comparable efficacy in treating 
diabetic microalbuminuria, and the combination of 
the two drugs did not add any further benefit. In this 
prospective, randomized clinical trial, the efficacy of 
treatment with enalapril or losartan, or both enalapril 
and losartan, was compared in patients with microal-
buminuria [24].
Moreover, a review by Mercier et al. [5] indicated 
that dual RAAS inhibition with ACE inhibitors, ARBs 
or ACE inhibitors, and direct renin inhibitors failed to 
improve cardiovascular or renal outcomes and predis-
posed patients to adverse events. Thus, more studies 
need to be conducted to assess the efficacy and safety 
of the ACEI plus ARB therapy [5].
Based on the reno-protective effects demonstrated 
above, ARBs (losartan, telmisartan high-dose irbe-
sartan) may be preferred for diabetic patients with 
albuminuria.
Guidelines on the role of ACEIs and ARBs 
on microalbuminuria in diabetic patients
American Diabetes Association (ADA)  
Guidelines
ADA recommends the following: “An ACE inhibitor 
or ARB, at the maximum tolerated dose is indicated 
for blood pressure treatment as first-line treatment 
for hypertension in patients with diabetes and urinary 
albumin-to-creatinine ratio (UACR) ≥ 300 mg/g cre-
atinine or 30–299 mg/g creatinine. If one class is not 
tolerated, then it should be replaced with the other” 
[25] (Figure 1).
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NICE guideline recommendations
Type 1 diabetes: 
 — “ACE inhibitors should be initiated with the usual 
precautions and titrate to the maximum dose in 
all adults with diagnosed nephropathy (including 
those with microalbuminuria alone) and type 1 
diabetes”. 
 — “If ACE inhibitors are not tolerated, then it should be 
replaced with angiotensin II receptor antagonists. 
The combination therapy is not recommended”.
Type 2 diabetes:
 — “Initiate ACE inhibitors with the usual precautions 
and titrate to the maximum dose in all individu-
als with confirmed raised albumin excretion rate 
(> 2.5 mg/mmol for men, > 3.5 mg/mmol for 
women)”.
 — “Replace an angiotensin II-receptor antagonist 
for an ACE inhibitor for a person with an abnor-
mal albumin:creatinine ratio if an ACE inhibitor is 
poorly tolerated” [26].
Figure 1. Recommendations by ADA for the treatment of confirmed hypertension in people with diabetes
Recommentations for the treatment of conrmed
hypertension in people with diabetes
Initial BP < 160/100 mm Hg
Albuminuria Albuminuria
Initial BP ≥ 160/100 mm Hg
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Assess BP control and adverse effects
Not meeting target or
adverse effects using a drug






Consider addition of mineralocorticold receptor antagonist;
refer to specialist with expertise in BP management
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Guidelines from National Institute for Health 
and Care Excellence (NICE) 2014 and Kidney 
Disease Outcomes Quality Initiative (KDOQI) 
2012
 — “Use an ACE inhibitor or an ARB in patients with 
diabetes and albuminuria, even for subjects with 
microalbuminuria and normal blood pressure” 
[27, 28]. 
Results and discussions
It is cited in the ADA guidelines that to reduce 
the risk of aggravation of kidney disease, treatment 
needs to be initiated with ACEIs or ARBs on patients 
with albuminuria (urine albumin-to-creatinine ratio 
≥ 30 mg/g) [25].
A systematic review and meta-analysis by Wang 
et al. [1] showed that ARBs significantly reduced the 
risks of ESRD by approximately 26% and doubling of 
the serum creatinine level by nearly 25% [1].
As per a meta-analysis of 28 studies by Vejakama 
et al., ACEI/ARB lead to persistent protective effect 
on renal functions over other antihypertensive drugs, 
predominantly CCBs, and placebo in patients with 
type 2 diabetes. This reno-protective benefit seems 
to be beyond antihypertensive effect as there was no 
difference in reduction in the blood pressure between 
ACEI/ARB and active comparators. In this study ACEI/ 
/ARB demonstrated significant reduction in the risk of 
two-fold rise in serum creatinine, macroalbuminuria, 
and albuminuria compared to other antihypertensive 
drugs [29].
An inhibition of the renin–angiotensin II system 
(RAS) seems to be very important in preventing or de-
laying albuminuria in diabetic patients. It is reported 
that the mechanism behind a decrease in albuminuria 
in diabetic nephropathy with ARBs, e.g. olmesartan, 
obstructs the podocyte apoptosis in the kidney [30]. 
An animal study showed a rise in p27 (Kip1) mRNA and 
protein expression in diabetic glomeruli and podocytes. 
An ARB therapy reduces p27 (Kip1) expression; this 
therapy helps reduce renal hypertrophy [31]. A pre-
clinical study illustrated a reduction in albuminuria and 
advancement in glomerulosclerosis type 2 diabetes with 
valsartan by decreasing podocyte injury, oxidative stress 
and inflammation in renal tissues [32].
A pilot study by Esmatjes et al. demonstrated 
reduction in TGF-beta1 plasma level and urinary al-
bumin excretion with losartan on hypertensive type 2 
diabetes mellitus patients with microalbuminuria. 
The researchers suggested TGF-b1 as an indicator of 
beneficial reno-protective effect with inhibition of 
the renin–angiotensin system. Such a mechanism of 
decrease in the synthesis of TGF-b for a beneficial reno-
protective effect with the use of losartan was further 
substantiated by Houlihan et al. through a study on 
hypertensive type 2 diabetic patients with elevated 
albumin excretion [33, 34].
ACEIs are also beneficial in blocking increased 
expression of TGF-b type II receptor in diabetic ne-
phropathy [35]. ACEIs also appeared to be responsible 
for an alteration in matrix degradation pathways and 
that may reduce matrix accumulation in diabetic ne-
phropathy [36].
Based on an animal study, Bonnet et al. suggested 
prevention of renal gene and protein expression of 
nephrin as a possible mechanism for the beneficial ef-
fect of ARBs in reducing proteinuria in hypertensive dia-
betics. The researchers used irbesartan in this study [37].
A preclinical study by Ertürküner et al. [38] indicates 
that perindopril helps prevent impairment in renal 
corpuscle (Mesangial matrix and podocyte) diabetic 
rats [38].
Cordonnier et al. projected another mechanism of 
inhibition for interstitial cell growth ARBs. Researchers 
found out that perindopril reduces excessive interstitial 
cell growth in patients with diabetic glomerulopathy 
suffering from hypertension [39].
Low-dose irbesartan therapy seems to be inad-
equate to protect the kidney due to inadequate inhibi-
tion of the RAAS in patients with type 2 diabetes and 
microalbuminuria. This inadequate inhibition of the 
RAAS was demonstrated by dose-dependent rise in 
plasma renin levels. Researchers also suggested evalu-
ation of a 300 mg dose of irbesartan. Implementation 
of high-dose irbesartan treatment offers a consistent 
decrease in microalbuminuria may be due to reversal 
of renal structural and/or biochemical anomalies that 
contribute to long-term renal protective effects [21].
A systematic review and meta-analysis of twelve 
randomized controlled trials done by Caldeira et al. 
leads to the conclusion that treatment with ARBs should 
be implemented in patients who cannot tolerate ACE 
inhibitors. The researchers noticed that ARBs lead to 
minimal incidences of cough and angioedema, which 
are common side effects of ACE inhibitors [40].
Conclusion
ACEIs or ARBs are considered to be the 1st line of 
therapy for both type 1 and 2 diabetic patients with 
microalbuminuria. ARBs are preferred for patients who 
cannot tolerate ACE inhibitors. ARBs (e.g. losartan 
or telmisartan or higher dose of irbesartan) may be 
preferred over ACEIs due to their predominant renal 
protective effect in addition to their blood pressure im-
proving beneficial effects of improving blood pressure 
in type 2 diabetic patients. However, the comparative 
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effects of ARBs and ACEIs in either type 1 or type 2 
diabetic patients with microalbuminuria need to be 
further evaluated.
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